Sonrotoclax Approved as a New Targeted Therapy for Mantle Cell Lymphoma
The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and...
Progress Against Cancer
The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and...
The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin...
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant...
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA)...
Simultaneously, previous accelerated approvals for nivolumab in relapsed/refractory advanced classical Hodgkin lymphoma were converted to full approvals. The U.S....
The FDA has approved teclistamab with daratumumab hyaluronidase-fihj for certain patients with pretreated multiple myeloma. The U.S. Food and...
Zongertinib was granted accelerated approval as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer with...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment...
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved...
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The...